CAR T Cell Therapy News
The California Institute for Regenerative Medicine today awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop CAR T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells.
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.
Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
The complex process of cell division is being studied at City of Hope by a team of stem cell biologists led by Leo David Wang, M.D., Ph.D.
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.
FDA approves tisagenlecleucel (commercial name Kymriah) CAR T cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
CAR T Cells Save Chuck Fata's Life
City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.
City of Hope today announced that it is a certified treatment center to administer tisagenlecleucel (commercial name Kymriah) chimeric antigen receptor (CAR) T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration (FDA) – to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.
Often unrecognized are the countless folks who work in the spaces between the lab and the clinic — people responsible for doing everything from manufacturing CAR T cells to gaining federal approval for new trials.